Associated Papers
In vivo Proximity & Spatial Proteomics with CRISPR Screening Identify STXBP1 as a Protective Modifier of α-synuclein Toxicity in Dopamine Neurons.
Shonai D et al.
Biorxiv : the Preprint Server for Biology, 2026
Neuropathology in genetic Parkinson's disease: a focused review of pathological and clinical findings.
Barbosa PM et al.
Journal of Neural Transmission (vienna, Austria : 1996), 2025
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.
Pitton Rissardo J et al.
Brain Sciences, 2025
Alpha-synuclein interacts with regulators of ATP homeostasis in mitochondria.
Serdiuk T et al.
Nature Communications, 2025
Amyloid fibril structures link CHCHD10 and CHCHD2 to neurodegeneration.
Lv G et al.
Nature Communications, 2025
Interplay of α-Synuclein Oligomers and Endoplasmic Reticulum Stress in Parkinson'S Disease: Insights into Cellular Dysfunctions.
Zeng H et al.
Inflammation, 2025
Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson's disease: From pathogenesis to potential therapeutic strategies.
Abdelaziz AM
International Immunopharmacology, 2025
A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson's disease.
Li D et al.
Npj Parkinson's Disease, 2025
Autophagy-NAD+ axis: emerging insights into neuronal homeostasis and neurodegenerative diseases.
Kocak G et al.
Frontiers in Molecular Biosciences, 2025
Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders.
Sidoryk-Węgrzynowicz M et al.
International Journal of Molecular Sciences, 2024
Structurally targeted mutagenesis identifies key residues supporting α-synuclein misfolding in multiple system atrophy.
Reis PM et al.
Journal of Parkinson's Disease, 2024
Posttranslational Modifications of α-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.
Hassanzadeh K et al.
Pharmacological Reviews, 2024
Correction to Supporting Information for Woerman et al., Familial Parkinson's point mutation abolishes multiple system atrophy prion replication.
Unknown Author
Proceedings of the National Academy of Sciences of the United States of America, 2024
Structurally targeted mutagenesis identifies key residues supporting α -synuclein misfolding in multiple system atrophy.
Reis PM et al.
Biorxiv : the Preprint Server for Biology, 2024
Parkinson's disease-associated mutations in α-synuclein alters its lipid-bound state.
Maltseva S et al.
Biophysical Journal, 2024
Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease.
Sharma K et al.
Molecular Biology Reports, 2024
Resequencing the complete SNCA locus in Indian patients with Parkinson's disease.
Kishore A et al.
Npj Parkinson's Disease, 2024
Innate immune activation in neurodegenerative diseases.
Castro-Gomez S et al.
Immunity, 2024
Alpha-synuclein regulates the repair of genomic DNA double-strand breaks in a DNA-PKcs-dependent manner.
Rose EP et al.
Biorxiv : the Preprint Server for Biology, 2024
Characterization of Molecular Tweezer Binding on α-Synuclein with Native Top-Down Mass Spectrometry and Ion Mobility-Mass Spectrometry Reveals a Mechanism for Aggregation Inhibition.
Lantz C et al.
Journal of the American Society for Mass Spectrometry, 2023
In Silico Evaluation of the Potential Association of the Pathogenic Mutations of Alpha Synuclein Protein with Induction of Synucleinopathies.
Elnageeb ME et al.
Diseases (basel, Switzerland), 2023
Role of Autophagy Pathway in Parkinson's Disease and Related Genetic Neurological Disorders.
Themistokleous C et al.
Journal of Molecular Biology, 2023
Interfacial properties of α-synuclein's Parkinsonian variants.
Mohapatra A et al.
Biophysical Chemistry, 2023
Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.
Sampognaro PJ et al.
Molecular Neurodegeneration, 2023
Mitochondrial dysfunction: A notable contributor to the progression of Alzheimer's and Parkinson's disease.
Olagunju AS et al.
Heliyon, 2023
Aggregation of Disordered Proteins Associated with Neurodegeneration.
Tsoi PS et al.
International Journal of Molecular Sciences, 2023
The Role of Membrane Affinity and Binding Modes in Alpha-Synuclein Regulation of Vesicle Release and Trafficking.
Das T et al.
Biomolecules, 2022
Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants.
Watt KJC et al.
The Journal of Biological Chemistry, 2022
DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family.
Cheng F et al.
Brain : a Journal of Neurology, 2022
Alpha-synuclein overexpression induces epigenomic dysregulation of glutamate signaling and locomotor pathways.
Schaffner SL et al.
Human Molecular Genetics, 2022
The Role of Rab Proteins in Parkinson's Disease Synaptopathy.
Bellucci A et al.
Biomedicines, 2022
Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.
Venkatesan D et al.
Journal of Molecular Neuroscience : Mn, 2022
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1.
Won SY et al.
Cell Death & Disease, 2022
Wide-Line NMR Melting Diagrams, Their Thermodynamic Interpretation, and Secondary Structure Predictions for A30P and E46K α-Synuclein.
Bokor M et al.
Acs Omega, 2022
Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of α-synuclein.
Ohgita T et al.
Scientific Reports, 2022
Change in the Oligomeric State of α-Synuclein Variants in Living Cells.
Fan HF et al.
Acs Chemical Neuroscience, 2022
Animal models of brain-first and body-first Parkinson's disease.
Van Den Berge N et al.
Neurobiology of Disease, 2022
An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.
Serratos IN et al.
Molecular Neurobiology, 2022
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.
Werner MH et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2022
Wild-Type α-Synuclein and Variants Occur in Different Disordered Dimers and Pre-Fibrillar Conformations in Early Stage of Aggregation.
Guzzo A et al.
Frontiers in Molecular Biosciences, 2022
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease.
Suvarna V et al.
Frontiers in Pharmacology, 2022
Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
Padilla-Godínez FJ et al.
International Journal of Molecular Sciences, 2021
Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders.
Shan FY et al.
Life (basel, Switzerland), 2021
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation.
Wang C et al.
Translational Neurodegeneration, 2021
Parkinson's Disease Genetics and Pathophysiology.
Vázquez-Vélez GE et al.
Annual Review of Neuroscience, 2021
Oxidative stress factors in Parkinson's disease.
Dorszewska J et al.
Neural Regeneration Research, 2021
Low chorionic villous succinate accumulation associates with recurrent spontaneous abortion risk.
Wang XH et al.
Nature Communications, 2021
Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: Implications for Parkinson's disease.
Feng ST et al.
The European Journal of Neuroscience, 2021
Hydration Thermodynamics of Familial Parkinson's Disease-Linked Mutants of α-Synuclein.
Aggarwal L et al.
Journal of Chemical Information and Modeling, 2021